Inotiv (Inotiv) Risk Assessment

View and export this data going back to 1997. Start your Free Trial

What is Inotiv Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Inotiv is: High Risk: High uncertainty.

Competitive Comparison of Inotiv's Risk Assessment

For the Diagnostics & Research subindustry, Inotiv's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inotiv's Risk Assessment Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Inotiv's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Inotiv's Risk Assessment falls into.

Inotiv (NAS:NOTV) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Inotiv Risk Assessment Related Terms

Thank you for viewing the detailed overview of Inotiv's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Inotiv (Inotiv) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Inotiv Inc (NAS:NOTV) » Definitions » Risk Assessment

Comparable Companies

STIM FONR BNR ACRS PRPH VNRX MDXH BDSX BIOQ PSNL TMO DHR IQV XSWX:LONN IDXX A MTD ICLR ILMN WAT

Traded in Other Exchanges

BS50:Germany

Address

2701 Kent Avenue, West Lafayette, IN, USA, 47906

Website

https://www.inotivco.com

Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery and development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, it supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through the RMS segment, it offers access to a wide range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It earns maximum revenue from RMS Segment.

Executives

John Gregory Beattie	officer: Chief Operating Officer	C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906
Michael Garrett	officer: Chief Commercial Officer	250 PEHLE DRIVE, SUITE 601, SADDLE BROOK NJ 07663
Andrea Castetter	officer: SVP, Gen. Counsel & Secretary	2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Mary Theresa Coelho	director	52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
John E Sagartz	director, officer: Chief Strategy Officer	19 WORTHINGTON ACCESS DRIVE, MARYLAND HEIGHTS MO 63043
David Landman	director	2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Robert Jr. Leasure	director, officer: President and CEO	C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Beth Taylor	officer: Chief Financial Officer	3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Jeffrey Arthur Krupp	officer: Chief Human Resources Officer	2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
William D Pitchford	officer: Chief Human Resources Officer	1000 SAGAMORE PARKWAY SOUTH, LAFAYETTE IN 47905
R Matthew Neff	director	535 N. COLLEGE DRIVE, CARMEL IN 46032
Jeffrey Brennan Freeman	officer: VP-Finance & Corp. Controller	2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Davis Gregory Cole	director	C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906
Nigel Brown	director	250 PEHLE AVENUE, SUITE 600, SADDLE BROOK NJ 07663
Scott Cragg	director	660 MADISON AVENUE, NEW YORK NY 10065